UnitedHealth Raises 2026 Earnings Outlook as Medical-Cost Management Supports Q3 Beat
UnitedHealth raised its 2026 adjusted earnings outlook to at least $20.50 per share after a Q3 beat, offering a key signal for managed-care sentiment.
Bristol Myers Squibb Gains on Dual Phase 3 Wins and CAMZYOS Label Expansion
Bristol Myers Squibb shares gained on dual Phase 3 wins, CAMZYOS expansion and fresh analyst commentary on its IPF pipeline.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Bristol Myers Squibb Stock Jumps 6.5% on Dual Phase 3 Wins and Expanded CAMZYOS Approval
Bristol Myers Squibb shares jumped 6.5% after two positive Phase 3 updates and expanded FDA approval for CAMZYOS strengt…
Syndax Stock Drops 12.2% After Axatilimab Trial Miss Raises Biotech Risk Concerns
Syndax shares fell 12.2% to $14.54 in pre-open trading after its MAXPIRe Phase 2 axatilimab trial did not meet expectati…
UnitedHealth Raises 2026 Profit Outlook as Q3 Beat Overcomes Medical-Cost Pressure
UnitedHealth topped Q3 estimates and raised its 2026 profit outlook, offering a closely watched signal for managed care …
STERIS to Buy Xodus Medical for $2.1 Billion in Surgical-Device Expansion
STERIS’s $2.1 billion purchase of Xodus Medical would broaden its surgical-device portfolio and underscore healthcare’s …
Solventum Seeks Offers for Health Information Systems Business in Potential Divestiture
Solventum is reportedly collecting offers for its Health Information Systems business, signaling a possible portfolio re…
Bristol Myers Squibb Jumps 6.5% After Twin Phase 3 Trial Wins
Bristol Myers Squibb rose 6.5% after two positive Phase 3 readouts, but mixed insider and guru positioning adds a note o…
Vaxcyte Stock Surges After $1.15 Billion Raise for VAX-31 Vaccine Program
Vaxcyte’s $1.15 billion public offering strengthens its balance sheet, supports VAX-31 development and reduces near-term…
STERIS’s $2.1 Billion Xodus Medical Deal Tests Healthcare M&A Appetite
STERIS’s $2.1 billion Xodus Medical agreement puts financing, dilution and medical-device M&A appetite under the microsc…
Bristol Myers Squibb Stock Jumps on Rare Double Phase 3 Success
BMY shares rose 5.7% to 6.5% after two positive Phase 3 readouts, putting pipeline value and analyst targets back in foc…